- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03826524
Dose d'épinéphrine : essai d'évaluation optimal versus standard (EpiDOSE)
Dose d'épinéphrine CanROC : essai d'évaluation optimal versus standard (essai CanROC EpiDOSE)
The objective of this randomized controlled trial is to evaluate whether a low cumulative dose of epinephrine ("low dose") is non-inferior to a standard cumulative dose of epinephrine ("standard dose") with respect to survival to hospital discharge among adults undergoing resuscitation for OHCA due to ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study is designed as a prospective, multicentre, single-blinded randomized controlled trial (RCT) where eligible OHCA patients are randomized to receive a low cumulative dose of epinephrine (low dose epinephrine, up to 2mg total) or a standard cumulative dose of epinephrine (standard dose epinephrine, up to 6mg total) in a 1:1 fashion.
Eligible OHCA patients will be treated by paramedics who will initiate cardiopulmonary resuscitation (CPR) and the delivery of defibrillation shocks per paramedic agencies' treatment protocols. After one defibrillation and when feasible, paramedics will establish peripheral intravenous (IV) access, and patients will be randomly allocated to either the low dose or standard dose treatment arm. Epinephrine doses (according to treatment assignment) will be administered every 3-5 minutes, based on current guidelines and paramedic protocols, until the first return of spontaneous circulation (ROSC) is achieved or if resuscitation has been terminated by the base hospital physician. Other medications (e.g. antiarrhythmics, magnesium, beta blockers) and interventions (e.g. intubation) may be interposed as required. Follow-up will take place using a combination of administrative databases (e.g. the Discharge Abstract Database and the National Ambulatory Care Reporting System) and telephone interviews.
This RCT will evaluate a fundamental change in the treatment of OHCA. The investigators hypothesize that a low cumulative dose of epinephrine will improve patient survival to hospital discharge compared to a standard cumulative dose of epinephrine. Please feel free to contact epidose@unityhealth.to for further information.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Theresa Aves, MSc
- Numéro de téléphone: 46787 416-864-6060
- E-mail: theresa.aves@unityhealth.to
Lieux d'étude
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8W 9P1
- Recrutement
- British Columbia Emergency Health Services (BCEHS)
-
Chercheur principal:
- Brian Grunau, MD
-
Contact:
- Helen Connolly
- Numéro de téléphone: 604-806-8753
- E-mail: HConnolly@providencehealth.bc.ca
-
-
Ontario
-
Brampton, Ontario, Canada, L6T 4B9
- Recrutement
- Peel Regional Paramedic Services
-
Chercheur principal:
- Sheldon Cheskes, MD
-
Contact:
- Theresa Aves
- Numéro de téléphone: 46787 416-864-6060
- E-mail: theresa.aves@unityhealth.to
-
London, Ontario, Canada, N6E 1R4
- Recrutement
- Middlesex-London Paramedic Service
-
Chercheur principal:
- Christian Vaillancourt, MD
-
Contact:
- Manya Charette
- Numéro de téléphone: 17758 613-798-5555
- E-mail: mancharette@ohri.ca
-
Sous-enquêteur:
- Matthew Davis, MD
-
Oakville, Ontario, Canada, L6M 3L1
- Recrutement
- Halton Region Paramedic Services
-
Chercheur principal:
- Sheldon Cheskes, MD
-
Contact:
- Theresa Aves
- Numéro de téléphone: 46787 416-864-6060
- E-mail: epidose@unityhealth.to
-
Ottawa, Ontario, Canada, K1H 1E2
- Recrutement
- Ottawa Paramedic Services
-
Chercheur principal:
- Christian Vaillancourt, MD
-
Contact:
- Manya Charette
- Numéro de téléphone: 17758 613-798-5555
- E-mail: mancharette@ohri.ca
-
Thunder Bay, Ontario, Canada, P7B 4X6
- Recrutement
- Superior North Emergency Medical Services
-
Chercheur principal:
- Christian Vaillancourt, MD
-
Contact:
- Manya Charette
- Numéro de téléphone: 17758 613-798-5555
- E-mail: mancharette@ohri.ca
-
Sous-enquêteur:
- David Savage, MD
-
Waterloo, Ontario, Canada, N2G 4J3
- Recrutement
- Region of Waterloo Paramedic Services
-
Contact:
- Kathy Winter, MD
- Numéro de téléphone: 71223 905-521-2100
- E-mail: winterkat@hhsc.ca
-
Chercheur principal:
- Paul Miller, MD
-
Windsor, Ontario, Canada, N9A 1N6
- Recrutement
- Essex-Windsor Emergency Health Services
-
Chercheur principal:
- Christian Vaillancourt, MD
-
Contact:
- Manya Charette
- Numéro de téléphone: 17758 613-798-5555
- E-mail: mancharette@ohri.ca
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7J 4M2
- Recrutement
- Medavie Health Services West
-
Contact:
- Tracy Wilson, PhD
- Numéro de téléphone: 306-655-2810
- E-mail: tracy.wilson@usask.ca
-
Chercheur principal:
- Andrew Leach, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Out-of-hospital cardiac arrest treated by paramedics AND
- Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics or fire services, AND
- Established intravenous vascular access
Exclusion Criteria:
- Known or apparent age <18 years
- Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics
- Cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden asphyxiation, etc.)
- Administration of intramuscular, endotracheal tube, or intraosseous epinephrine
- Prisoners or persons in police custody
- Known allergy or sensitivity to epinephrine
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Low Dose Epinephrine
Epinephrine up to 2mg total |
Epinephrine 1mg 1:10000 (10cc) per dose
Autres noms:
|
|
Comparateur actif: Standard Dose Epinephrine
Epinephrine up to 6mg total |
Epinephrine 1mg 1:10000 (10cc) per dose
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Survival to hospital discharge
Délai: Through study completion (up to 5 years)
|
Individuals discharged alive from hospital |
Through study completion (up to 5 years)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Return of spontaneous circulation in out-of-hospital setting
Délai: Through study completion (up to 5 years)
|
Return of spontaneous circulation in the field |
Through study completion (up to 5 years)
|
|
Survival to emergency department arrival
Délai: Through study completion (up to 5 years)
|
Individuals alive upon arrival to a hospital emergency department |
Through study completion (up to 5 years)
|
|
Survival to admission with death prior to discharge
Délai: Through study completion (up to 5 years)
|
Individuals alive upon hospital admission who die in-hospital before being discharged |
Through study completion (up to 5 years)
|
|
Survival to discharge outside of a long-term healthcare facility e.g. nursing home
Délai: Through study completion (up to 5 years)
|
Individuals discharged alive from hospital to a care facility |
Through study completion (up to 5 years)
|
|
Modified Rankin Scale (mRS) score
Délai: 12+/-3 months
|
Assessment of neurological function, scores range from 0 to 6 where higher scores indicate worse neurological function (0=no symptoms, 6=dead) |
12+/-3 months
|
|
Health Utility Index-3 (HUI-3) score
Délai: 12+/-3 months
|
Assessment of quality of life, scores range from -0.36 to 1 where higher scores indicate better quality life (negative scores=a state worse than being dead, 0=dead, 1=perfect health) |
12+/-3 months
|
|
Hospital Anxiety and Depression Scale score
Délai: 12+/-3 months
|
Assessment of quality of life, scores range from 0 to 21 where higher scores indicate more anxiety/depression |
12+/-3 months
|
|
Length of stay in hospital
Délai: Through study completion (up to 5 years)
|
Length of time an individual remained in-hospital (length in days) |
Through study completion (up to 5 years)
|
|
Length of stay in critical care unit
Délai: Through study completion (up to 5 years)
|
Length of time an individual remained in a crucial care unit (length in days) |
Through study completion (up to 5 years)
|
|
Survival post-arrest
Délai: Up to 5 years
|
Survival following hospital discharge, up to 5 years |
Up to 5 years
|
|
Recurrent cardiac arrest(s)
Délai: Up to 5 years
|
Number of cardiac arrests following the index arrest |
Up to 5 years
|
|
ICD implant post-arrest
Délai: Up to 5 years
|
Whether an implantable cardioverter defibrillator was implanted post-arrest |
Up to 5 years
|
|
Cardiovascular re-hospitalization(s)
Délai: Up to 5 years
|
Number of cardiovascular re-hospitalizations |
Up to 5 years
|
|
All-cause re-hospitalizations(s)
Délai: Up to 5 years
|
Number of re-hospitalizations for any reason |
Up to 5 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Paul Dorian, MD, MSc, Unity Health Toronto
- Chercheur principal: Steve Lin, MD, MSc, Unity Health Toronto
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies cardiaques
- Arythmies cardiaques
- Décès
- Arrêt cardiaque
- Mort subite
- Conditions pathologiques, signes et symptômes
- Décès, Soudain, Cardiaque
- Arrêt cardiaque hors hôpital
- Fibrillation ventriculaire
- Produits chimiques organiques
- Hydrocarbures
- Hydrocarbures, cyclique
- Hydrocarbures, aromatique
- Amines
- Catéchols
- Phénols
- Dérivés de benzène
- Alcools
- Alcools amino
- Éthanolamines
- Monoamines biogéniques
- Amines biogéniques
- Catécholamines
- Épinéphrine
Autres numéros d'identification d'étude
- EpiDOSE Protocol Version 4.0
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .